Zhejiang Tianyu Pharmaceutical (300702.SZ) subsidiary receives drug registration certificate for Ibrutinib Capsules

date
17:56 19/11/2026
avatar
GMT Eight
Zhejiang Tianyu Pharmaceutical (300702.SZ) announced that its wholly-owned subsidiary, Zhejiang Nuode Pharmaceutical Co., Ltd., recently received the Drug Registration Certificate for Ibrutinib Capsules approved and issued by the National Medical Products Administration. The drug is indicated for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrm's macroglobulinemia, and others. According to statistics, the sales of Ibrutinib Capsules in domestic sample hospitals and urban brick-and-mortar pharmacies in 2025 were approximately RMB399 million (data sourced from Menet).
Zhejiang Tianyu Pharmaceutical (300702.SZ) announced that its wholly-owned subsidiary, Zhejiang Nuode Pharmaceutical Co., Ltd., recently received the Drug Registration Certificate for Ibrutinib Capsules approved and issued by the National Medical Products Administration. The drug is indicated for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrm's macroglobulinemia, and other conditions. According to statistics, the sales of Ibrutinib Capsules in domestic sample hospitals and urban brick-and-mortar pharmacies in 2025 amounted to approximately RMB399 million (data sourced from Menet).